Newer Antidepressants Work 2 Ways
Key points
- New research shows that the popular, and sometimes controversial, antidepressants known as selective serotonin reuptake inhibitors (SSRIs) boost serotonin levels on two fronts.
- The finding could explain why these medications often take weeks to work, the scientists report in the April 7 issue of Neuron.
- In addition to boosting serotonin levels, this family of antidepressants apparently also "hijacks" the dopamine signaling system, causing it to affect serotonin levels as well.
- The use of SSRIs, especially by children, came into question last fall following reports of increased thoughts of suicide and attempts among young, depressed patients.
New research shows that the popular, and sometimes controversial, antidepressants known as selective serotonin reuptake inhibitors (SSRIs) boost serotonin levels on two fronts.
The finding could explain why these medications often take weeks to work, the scientists report in the April 7 issue of Neuron. Apparently, SSRIs kick off a two-pronged process that puts serotonin levels back into balance. Serotonin is a brain chemical that scientists believe is in short supply in depressed people.
In addition to boosting serotonin levels, this family of antidepressants apparently also "hijacks" the dopamine signaling system, causing it to affect serotonin levels as well.
The use of SSRIs, especially by children, came into question last fall following reports of increased thoughts of suicide and attempts among young, depressed patients. The U.S. Food and Drug Administration responded by mandating a black box warning on the use of these drugs in children and teenagers.
"We have known about these interrelationships," said Dr. Fred Quitkin, director of the depression evaluation service at the New York State Psychiatric Institute. "It's of interest, but no one knows what it means."
"The brain is so incredibly complicated," said Dr. Eugenio M. Rothe, director of the child and adolescent psychiatry clinic at Jackson Memorial Hospital in Miami, Fla., and an associate professor of psychiatry at the University of Miami School of Medicine. "More and more things have yet to be discovered. The brain is the final frontier."
Many of the millions of Americans afflicted with depression have a disorder in the brain's reward system, explained study author Fu-Ming Zhou, an assistant professor of pharmacology at the University of Tennessee College of Medicine in Memphis. Zhou conducted the study while at the Baylor College of Medicine.
"A large body of research indicates that the dopamine system is the most important player in the reward system," he added.
Often, however, depression is treated with medications that affect the serotonin system. SSRIs block the reuptake of serotonin back into the nerve terminals.
In a healthy person, serotonin is stored in nerve terminals and then released into the spaces between neurons. Problems occur when the neurotransmitter is sucked back into the terminal, a process called reuptake. "This limits the level or availability of serotonin near the nerve terminals," Zhou said. "There is a possibility, which remains to be proven, that the local serotonin level near these nerve terminals is abnormally low in depressed patients."
"When a patient takes an SSRI, the reuptake process is inhibited, leading to increased serotonin levels around the nerve terminal, and also restored or enhanced serotonin signaling," he continued. "This restored or enhanced signaling is often believed to be the major therapeutic mechanism of SSRIs."
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Medicines & Treatments →Banning a drug carrying some risk is not always best prescription
"This is a very confusing situation," a top Food and Drug Administration scientist, Sandra Kweder, said of the controversy over Celebrex and other popular pain relievers. If the FDA is confused, imagine the feelings of…
31 December 2004
